Meeting
2023 ASCO Annual Meeting
Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors.
Authors
Sunil Sharma
Honor Health, Scottsdale, AZ
Sunil Sharma , Alexander Starodub , Nong Xu , Arvind Chaudhry , Meili Sun , Meredith Pelster , Yinjia Fu , Xinyu Zhang , Zhao Huang , Wenyu Liu , Karl Hsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT05065710
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2537)
DOI
10.1200/JCO.2023.41.16_suppl.2537
Abstract #
2537
Poster Bd #
379
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.
First Author: Nashat Y. Gabrail
Poster
2024 ASCO Annual Meeting
Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.
First Author: Judy S. Wang
Poster
2023 ASCO Annual Meeting
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.
First Author: Yelena Y. Janjigian
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors.
First Author: Anthony W. Tolcher